Korean J Hematol 2007; 42(2):
Published online June 30, 2007
https://doi.org/10.5045/kjh.2007.42.2.176
© The Korean Society of Hematology
김진수, 임주한, 이현규, 박현민, 이문희, 김철수
인하대학교병원 혈액종양내과,
서울대학교병원 혈액종양내과
Hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome (MDS), but the prevalence of the disease in elderly people limits broad application of the procedure, particularly in lower risk group. Azacitidine has been recently approved by the U.S. Food and Drug Administration for MDS regardless of subtype on French-American-British classification. Adverse effects of azacitidine include gastrointestinal, hematological and infusion-related reactions. Azacitidine induced hepatotoxicity has been reported mainly in patients with previous hepatobiliary disease, e.g., extensive tumor infiltration in liver, liver cirrhosis and cholelithiasis. We report here a case of azacitidine-induced hepatitis under no predisposition to hepatobiliary disease.
Keywords Myelodysplastic syndrome, Azacitidine, Adverse effects, Hepatitis, Toxic, Hepatitis, Drug-induced
Korean J Hematol 2007; 42(2): 176-179
Published online June 30, 2007 https://doi.org/10.5045/kjh.2007.42.2.176
Copyright © The Korean Society of Hematology.
김진수, 임주한, 이현규, 박현민, 이문희, 김철수
인하대학교병원 혈액종양내과,
서울대학교병원 혈액종양내과
Jin Soo Kim, Joo Han Lim, Hyeon Gyu Yi, Hyun min Park, Moon Hee Lee, Chul Soo Kim
Division of Hematology, Oncology, Departments of Medicine, Inha University Hospital, Incheon
Seoul National University Hospital, Seoul, Korea
Hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome (MDS), but the prevalence of the disease in elderly people limits broad application of the procedure, particularly in lower risk group. Azacitidine has been recently approved by the U.S. Food and Drug Administration for MDS regardless of subtype on French-American-British classification. Adverse effects of azacitidine include gastrointestinal, hematological and infusion-related reactions. Azacitidine induced hepatotoxicity has been reported mainly in patients with previous hepatobiliary disease, e.g., extensive tumor infiltration in liver, liver cirrhosis and cholelithiasis. We report here a case of azacitidine-induced hepatitis under no predisposition to hepatobiliary disease.
Keywords: Myelodysplastic syndrome, Azacitidine, Adverse effects, Hepatitis, Toxic, Hepatitis, Drug-induced
Kyung-Lim Hwang, Moo-Kon Song, Ho-Jin Shin, Hae-Jung Na, Dong-Hun Shin, Joong-Keun Kim, Joon-Ho Moon, Jae-Sook Ahn, Ik-Chan Song, Junshik Hong, Gyeong-won Lee, and Joo-Seop Chung
Blood Res 2014; 49(4): 234-240Junshik Hong, Yoo Jin Lee, Sung Hwa Bae, Jun Ho Yi, Sungwoo Park, Myung Hee Chang, Young Hoon Park, Shin Young Hyun, Joo-Seop Chung, Ji Eun Jang, Joo Young Jung, So-Yeon Jeon, Seo-Young Song, Hawk Kim, Dae Sik Kim, Sung-Hyun Kim, Min Kyoung Kim, Sang Hoon Han, Seonyang Park, Yoo-Jin Kim, Je-Hwan Lee, on behalf of the AML/MDS Working Party of the Korean Society of Hematology
Blood Res 2021; 56(2): 102-108Meerim Park
Blood Res 2021; 56(S1): S34-S38